SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive...
Main Authors: | Swetha R. Kanduri, Karthik Kovvuru, Panupong Hansrivijit, Charat Thongprayoon, Saraschandra Vallabhajosyula, Aleksandra I. Pivovarova, Api Chewcharat, Vishnu Garla, Juan Medaura, Wisit Cheungpasitporn |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/9/2723 |
Similar Items
-
Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis
by: Api Chewcharat, et al.
Published: (2020-11-01) -
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
by: Jennifer Matthews, et al.
Published: (2023-09-01) -
Predicting Acute Kidney Injury after Cardiac Surgery by Machine Learning Approaches
by: Charat Thongprayoon, et al.
Published: (2020-06-01) -
Promises of Big Data and Artificial Intelligence in Nephrology and Transplantation
by: Charat Thongprayoon, et al.
Published: (2020-04-01) -
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)